RGS6 is both necessary and sufficient to drive cardiac damage resulting from chronic elevations in blood glucose via a KLF4/miR-30e/CaMKIIδ-dependent mechanism, identifying RGS6/KLF4 as key sources of pathogenic cardiac damage in individuals with diabetes mellitus.
Key Findings
Results
High glucose triggers RGS6 upregulation in human and murine cardiomyocytes, hyperglycemic mouse hearts, and cardiac tissue from individuals with heart failure and a history of diabetes.
RGS6 upregulation was observed across multiple systems: isolated human cardiomyocytes, isolated murine cardiomyocytes, hearts of hyperglycemic mice, and human cardiac tissue samples from heart failure patients with diabetic history.
The finding establishes translational relevance by demonstrating the same molecular change in both preclinical models and human tissue.
This represents a consistent pattern of RGS6 induction under hyperglycemic conditions across species and tissue contexts.
Results
RGS6 modulation in isolated cardiomyocytes produced corresponding changes in expression of the transcription factor KLF4, identified as a novel RGS6-interacting protein.
KLF4 (Krüppel-like factor 4) was identified as a novel RGS6-interacting protein.
Modulation of RGS6 expression — both upregulation and downregulation — resulted in corresponding directional changes in KLF4 expression.
This interaction places KLF4 downstream of RGS6 in the signaling cascade driving diabetic cardiomyopathy.
Results
RGS6-dependent, KLF4-mediated suppression of miR-30e increased expression of the pro-apoptotic target CaMKIIδ in cardiomyocytes.
KLF4 was found to suppress microRNA 30e (miR-30e) in a manner dependent on upstream RGS6 signaling.
CaMKIIδ (Ca2+/calmodulin-dependent kinase II delta isoform) was identified as a pro-apoptotic target of miR-30e.
Suppression of miR-30e by KLF4 de-repressed CaMKIIδ expression, promoting apoptotic signaling.
This establishes a linear signaling axis: RGS6 → KLF4 → miR-30e suppression → CaMKIIδ upregulation → apoptosis.
Results
Inhibition of KLF4 or CaMKII, or overexpression of miR-30e, mitigated the deleterious impact of RGS6 overexpression on myocyte viability.
Three independent interventions — KLF4 inhibition, CaMKII inhibition, and miR-30e overexpression — each rescued myocyte viability under conditions of RGS6 overexpression.
These rescue experiments confirm the functional necessity of each downstream component in the RGS6-driven apoptotic pathway.
The findings validate KLF4, miR-30e, and CaMKIIδ as potential therapeutic targets within this pathway.
Results
Cardiac-specific RGS6 knockdown provided marked protection against hyperglycemia-driven oxidative stress, mitochondrial dysfunction, and activation of the intrinsic mitochondrial apoptosis pathway in the murine myocardium.
Cardiac-specific knockdown was used to establish the necessity of RGS6 for hyperglycemia-induced cardiac pathology in vivo.
Protection was observed across multiple pathological endpoints: oxidative stress, mitochondrial dysfunction, and intrinsic mitochondrial apoptosis pathway activation.
These findings demonstrate that RGS6 is required for the full spectrum of hyperglycemia-induced myocardial damage in mice.
Results
Inhibition of KLF4 decreased cardiotoxicity resulting from viral overexpression of RGS6 in mouse heart.
RGS6 was overexpressed in mouse hearts via viral delivery to model gain-of-function conditions.
KLF4 inhibition in vivo was sufficient to reduce cardiac toxicity caused by RGS6 overexpression.
This in vivo rescue experiment confirms KLF4 as a functionally relevant downstream mediator of RGS6-driven cardiac damage in a living organism.
Results
RGS6 was found to be both necessary and sufficient to drive cardiac damage resulting from chronic elevations in blood glucose.
Necessity was established through cardiac-specific knockdown experiments showing protection from hyperglycemia-induced damage.
Sufficiency was established through viral overexpression experiments showing that RGS6 alone could induce cardiotoxic effects.
Together, these gain- and loss-of-function approaches position RGS6 as a central driver of diabetic cardiomyopathy.
The authors conclude that 'RGS6/KLF4 as key sources of pathogenic cardiac damage in individuals with DM.'
What This Means
This research suggests that a protein called RGS6 plays a central role in the heart damage that occurs in people with diabetes. When blood sugar is chronically high, RGS6 levels rise in heart muscle cells (cardiomyocytes). This elevated RGS6 then activates a chain reaction: it increases a transcription factor called KLF4, which suppresses a small regulatory molecule called miR-30e, which in turn allows a cell-death-promoting enzyme called CaMKIIδ to become overactive. The end result is that heart muscle cells die — a process that contributes to heart failure, the leading cause of death in people with diabetes.
The researchers validated this pathway using multiple experimental approaches. When they blocked RGS6 specifically in heart tissue of diabetic mice, the hearts were substantially protected from oxidative stress, mitochondrial damage, and programmed cell death. Conversely, when they artificially increased RGS6 in mouse hearts, it caused heart damage — and that damage was reduced when KLF4 was inhibited. Blocking any single step in the chain (KLF4, CaMKII, or restoring miR-30e) was enough to protect heart cells from the effects of excess RGS6. Importantly, elevated RGS6 was also found in heart tissue samples from human patients with heart failure who had a history of diabetes, suggesting the findings are relevant to human disease.
This research suggests that the RGS6/KLF4 signaling axis could represent a new target for treating or preventing diabetic cardiomyopathy, a condition for which no effective treatments currently exist. By identifying a specific molecular pathway linking high blood sugar to heart muscle cell death, this work lays groundwork for potential future therapies aimed at interrupting this damaging cascade in people with diabetes.
Sengar A, Chakraborti S, Lye A, Verma S, Kumar M, Kumar D, et al.. (2026). RGS6 drives myocyte loss in the diabetic heart via a KLF4/miR-30e/CaMKII-dependent mechanism.. Molecular and cellular endocrinology. https://doi.org/10.1016/j.mce.2026.112895